Type 1 Diabetes and Pituitary Dysfunction from Immune Checkpoint Inhibitors: Clinical Features and HLA

Watercolor-style illustration of antibodies, the pituitary and an HLA label, representing a study of immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction.

Journal Club of the Suwanai · Cancer Immunotherapy & Endocrinology

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment. They can also unleash immune attacks on the body’s own organs, and endocrine glands are frequent targets.

In 2023, Endocrine published a study of the clinical features and human leukocyte antigen (HLA) profiles of patients with ICI-induced type 1 diabetes and pituitary dysfunction. It was a prospective study at Tokyo Medical University Hospital, and I was the second author. Read the original paper ↗

Key point: different timing, and what HLA tells us ↓

TOC

Why it matters

ICI-induced type 1 diabetes can abruptly abolish insulin secretion and cause diabetic ketoacidosis. Pituitary dysfunction can lead to cortisol deficiency and life-threatening adrenal crisis. Both are rare but serious, and clinical data have been scarce.

Methods

We prospectively followed patients receiving ICIs at our hospital from September 2017 to June 2022. For those who developed ICI-induced type 1 diabetes (ICI-T1D) or pituitary dysfunction (ICI-PD), we collected clinical data and performed HLA typing by next-generation sequencing, comparing results with previously reported healthy Japanese controls.

Results

patients on ICIs914
type 1 diabetes6
pituitary dysfunction15

Source: Hara et al., Endocrine (2023).

Mean time from ICI initiation to onset was 492 ± 196 days for type 1 diabetes and 191 ± 169 days for pituitary dysfunction. Two of the six patients with type 1 diabetes were positive for anti-GAD antibodies.

HLA-DR11, -Cw10, -B61, -DRB1*11:01 and -C*03:04 were more frequent in ICI-T1D, and HLA-DR15 and -DRB1*15:02 in ICI-PD, than in controls.

Journal Club view: different timing, and what HLA tells us

Clinically striking is that type 1 diabetes often appeared more than a year after starting treatment. Monitoring glucose and symptoms must continue long after the early phase of therapy. Many cases were anti-GAD negative, so antibody testing alone cannot predict the event.

HLA shapes what the immune system recognizes. Associations with particular HLA types could help predict susceptibility, but the numbers (6 and 15 cases) are small and the comparison relied on published control data, so replication in other cohorts is needed.

Oncology and endocrinology together

As ICI use expands, collaboration between oncologists and endocrinologists becomes ever more important. Recognizing thirst and polyuria, or fatigue and loss of appetite suggesting adrenal insufficiency, early can save lives.

Related articles

REFERENCE

Hara N, Suwanai H, Yakou F, Ishii K, Iwasaki H, Abe H, Shikuma J, Sakai H, Miwa T, Suzuki R. Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study. Endocrine. 2023;81(3):477–483.
doi:10.1007/s12020-023-03394-8 ↗

This article is an independent English summary and commentary based on the original paper. No figures are reproduced.

All Journal Club of the Suwanai articles →

Let's share this post !
TOC